loureirin b has been researched along with Bone Loss, Osteoclastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Fan, Y; Fang, H; He, W; Huang, H; Li, W; Liu, Y; Mo, L; Wang, H; Xu, J; Zhang, J; Zhou, C | 1 |
| Chen, K; Chen, L; Chen, Z; Deng, Z; He, W; Kenny, J; Liu, Y; Song, D; Sun, Y; Tickner, J; Wang, C; Wang, G; Wang, H; Xu, J; Zhang, Q; Zhou, C | 1 |
2 other study(ies) available for loureirin b and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Loureirin B downregulates osteoclast differentiation of bone marrow macrophages by targeting the MAPK signaling pathway.
Topics: Bone Marrow; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Humans; Macrophages; Molecular Docking Simulation; Osteoclasts; RANK Ligand; Resins, Plant; Signal Transduction; Vacuolar Proton-Translocating ATPases | 2022 |
Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Bone Resorption; Cell Differentiation; Cell Proliferation; Durapatite; Female; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; RANK Ligand; Reactive Oxygen Species; Resins, Plant | 2019 |